title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Acknowledgements | STUART | We gratefully acknowledge the patients and their families for taking part of this study. The authors also acknowledge all the COMBAT-CF clinicians, nurses, study coordinators and support personnel for their invaluable contribution to this study. J.A.C.-M. thanks the director of the Curtin Health and Innovation Research... | PMC10262387 | |
Authors’ contributions | Conceptualization, F.O.G., S.M.S., J.A.C.-M. and F.J.R.; Methodology, M.S. and J.A.C.-M.; Formal Analysis, J.A.C.-M. and S.P.A.-R.; Investigation, J.A.C.-M. and M.S.; Resources, S.M.S.; P.D.S. and R.S.W.; Writing-Original Draft Preparation, J.A.C.-M. and F.O.G.; Writing – Review & Editing, J.A.C.-M., M.S., S.P.A.-R., F... | PMC10262387 | ||
Funding | MRCG-2018–16 | CYSTIC FIBROSIS, THORACIC, BROWN | S.M.S. received funding from the US Cystic Fibrosis Foundation to develop the COMBAT-CF trial (STICK10K0, STICK19K0). This work was funded in part by grants awarded by the Health Research Board (HRB-ILP-POR-2019–004), the Irish Thoracic Society (MRCG-2018–16 and MRCG-2014–6), the US Cystic Fibrosis Foundation (OGARA171... | PMC10262387 |
Availability of data and materials | All the sequencing data generated in this study have been deposited in the Sequencing Read Archive (BIOPROJECT PRJNA819196). | PMC10262387 | ||
Declarations | PMC10262387 | |||
Ethics approval and consent to participate | This ancillary study was part of the exploratory outcomes of the COMBAT CF study protocol. Site-specific hospital Human Research Ethics Committee approved the COMBAT-CF trial and informed consent was obtained from parents/guardians. | PMC10262387 | ||
Consent for publication | Not applicable. | PMC10262387 | ||
Competing interests | The authors declare no competing interests | PMC10262387 | ||
References | PMC10262387 | |||
Objective | rectosigmoid junction cancer, AJCC, Cancer | CANCER, RECTOSIGMOID JUNCTION CANCER | The definition of rectosigmoid junction (RSJ) is still in debate. The treatment and prognosis of patients with rectosigmoid junction cancer (RSJC) and positive lymph nodes (PLN-RSJCs) are mostly based on the American Joint Committee on Cancer (AJCC) staging system. Our study aims to assist clinicians in creating a more... | PMC10193748 |
Methods | Based on the Surveillance, Epidemiology, and End Results (SEER) database, we extracted 3384 patients with PLN-RSJCs and randomly divided them into development ( | PMC10193748 | ||
Results | tumor, AJCC | TUMOR | Age, marital, chemotherapy, AJCC stage, T and N stage of TNM system, tumor size, and regional lymph nodes were selected as independent risk factors and included in the nomogram model. The C-index of this nomogram in the development (0.751;0.737–0.765) and validation cohorts (0.750;0.764–0.736) were more significant tha... | PMC10193748 |
Conclusions | We established an accurate nomogram model for PLN-RSJCs, intended to support clinicians in the treatment and follow-up of patients.
| PMC10193748 | ||
Keywords | PMC10193748 | |||
Introduction | death, colorectal cancer, cancer, lung cancer, Colorectal cancer, Cancer | COLORECTAL CANCER, CANCER, LUNG CANCER, COLORECTAL CANCER, CANCER | According to the 2022 Cancer Statistics Report, about 609,360 people died from cancer in the United States. Colorectal cancer is the second leading cause of death, after lung cancer [The nomogram model is a digital simulation tool widely used in clinical research and its results can be recognized by the public [The Sur... | PMC10193748 |
Methods | PMC10193748 | |||
Patient selection and data processing | Data from PLN-RSJCs patients were selected from the SEER database using the SEER*Stat software version 8.4.0 (Data screening flow chart | PMC10193748 | ||
Variables defined | tumor, T stage | TUMOR | The variables in the selected cohort included: age, sex, race, marital, AJCC stage (7th), T stage, N stage, summary stage, radiotherapy, chemotherapy, tumor size, examined and positive regional nodes. To facilitate the analysis, several continuous variables (age, tumor size, examined regional nodes, and positive region... | PMC10193748 |
Statistical analysis | REGRESSION | For the analysis of continuous and categorical variables in both development and validation cohort, the T and Chi-square tests were used. Univariate COX regression was used to extract the potential significant predictors in the development cohort. Predictors with To assess the performance of the model, we used concorda... | PMC10193748 | |
Results | PMC10193748 | |||
Characterization of eligible patients | The PLN-RSJCs patients (Demographics and clinical characteristics of eligible patients | PMC10193748 | ||
Nomogram construction | Based on the previous results of multivariate analysis in the development cohort, we integrated these independent prognostic factors to establish a nomogram model for OS prediction in PLN-RSJCs (Fig. Nomogram for OS prediction in PLN-RSJCsNomogram scoring system | PMC10193748 | ||
Validation of the nomogram | In the development cohort, the calculated C-index of the generated nomogram for patient OS was 0.751 (0.737–0.765), which was more significant than that of the 7th AJCC stage 0.681 (0.665–0.697). Additionally, the performances of the nomogram were assessed by ROC curves, with AUC values of 0.845, 0.808 and 0.800 for 1-... | PMC10193748 | ||
Performance of the nomogram in patient of low risk group and high risk group | The development cohort was stratified in two subgroups, according to the obtained score: low risk group: score < 94 points; high risk group: score ≥ 94 points. Kaplan–Meier survival curves showed a significant difference in OS between the two groups (Kaplan–Meier overall survival curves of PLN-RSJCs with different risk... | PMC10193748 | ||
Acknowledgements | No applicable. | PMC10193748 | ||
Special statement | All methods were carried out in accordance with relevant guidelines and regulations. | PMC10193748 | ||
Authors’ contributions | Wu Yanlong and Wang Yibing designed the research study. Wu Yanlong and Wu Yunxiao took responsibility for statistical analyses. Wu Yanlong wrote the manuscript. Wang Yibing evaluated and revised the manuscript. The author(s) read and approved the final manuscript. | PMC10193748 | ||
Funding | This work was supported by the following funds: Jiang xi Youth Science Fundation (20161BAB215250); Youth Fundation of Second Affiliated Hospital of Nanchang University (2016YNQN12029); Jiangxi Provincial Health Fund for Traditional Chinese Medicine (2019A027); Jiangxi Health and Family Planning Commission Fundation (20... | PMC10193748 | ||
Availability of data and materials | If anyone wants to request the data from this study,please contact the author named Wu Yan long(wuyanlong578@126.com). | PMC10193748 | ||
Declarations | PMC10193748 | |||
Ethics approval and consent to participate | All methods were carried out in accordance with relevant guidelines and regulations. Ethical approval for study was obtained from second Affiliated Hospital of Nanchang University Medical Research Ethics Committee. Informed consent was obtained from all the participants.We declare that none of the work contained in thi... | PMC10193748 | ||
Consent for publication | No applicable. | PMC10193748 | ||
Competing interests | The authors declare no competing interests. | PMC10193748 | ||
References | PMC10193748 | |||
Abstract | CC and NCH are joint senior authors.MAVIDOS Trial Group: Nigel K. Arden, Andrew Carr, Elaine M. Dennison, Richard Eastell, M Zulf Mughal. | PMC10470377 | ||
Background | PPH | PRETERM BIRTH, POST-PARTUM HAEMORRHAGE | Observational studies relating maternal 25-hydroxyvitamin D status to timing and mode of delivery have reported inconsistent results. We assessed the effect of antenatal cholecalciferol supplementation on the incidence of preterm birth, delivery mode and post-partum haemorrhage (PPH). | PMC10470377 |
Methods | PPH, blood loss | BLOOD LOSS | MAVIDOS was a randomized, double-blind, placebo-controlled trial of 1000 IU/day cholecalciferol from 14 weeks’ gestation until delivery. Gestational age, mode of delivery [categorized as spontaneous vaginal delivery (SVD), instrumental (including forceps and vacuum extraction) or Caesarean section] and PPH (>500 ml est... | PMC10470377 |
Results | PRETERM BIRTH | A total of 965 women participated in the study until delivery. Gestation at birth and incidence of preterm birth (cholecalciferol 5.7%, placebo 4.5%, | PMC10470377 | |
Conclusions | PRETERM BIRTH | Antenatal cholecalciferol supplementation did not alter timing of birth or prevalence of preterm birth but demonstrated a possible effect on the likelihood of SVD. | PMC10470377 | |
Background | rickets, seizures | PRETERM BIRTH, RICKETS, POST-PARTUM HAEMORRHAGE, CARDIOMYOPATHY, VITAMIN D DEFICIENCY, VITAMIN D DEFICIENCY | Vitamin D deficiency in pregnancy is common. In a study of predominately White women in the south of the UK, 31% had a serum 25(OH)D < 50 nmol/l (typically considered ‘insufficient’The primary function of vitamin D is in calcium and phosphate homeostasis and severe maternal vitamin D deficiency can result in neonatal h... | PMC10470377 |
Methods | PMC10470377 | |||
The maternal vitamin D osteoporosis study | hyperparathyroidism, ’, foetal anomalies, Osteoporosis, hypercalciuria, renal stones | HYPERPARATHYROIDISM, METABOLIC BONE DISEASE, OSTEOPOROSIS, EARLY PREGNANCY | The Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a multicentre, double-blind, randomized, placebo-controlled trial of vitamin D supplementation in pregnancy. The primary outcome was neonatal bone mass. A detailed description of the study methodsWomen attending one of three United Kingdom (UK) hospitals [Universi... | PMC10470377 |
Intervention | Participants were randomized to either cholecalciferol 1000 IU/day or matched placebo [Merck KGaA, (Darmstadt, Germany)/Sharp Clinical Services (Crickhowell, UK; previously DHP-Bilcare)], commenced before 17 weeks’ gestation. Packs of medication were randomly assigned in a 1:1 ratio by a computer-generated sequence in ... | PMC10470377 | ||
Outcomes | PMC10470377 | |||
Maternal assessments during pregnancy | Prior to commencing the study medication, and again at 34 weeks’ gestation, the women attended the research centre for a detailed assessment lifestyle and health (smoking, medical history, current medication use) and use of vitamin D supplementation using interviewer-led questionnaires. Height and weight were measured ... | PMC10470377 | ||
Assessment of 25(OH)D | Non-fasted venous blood | Non-fasted venous blood samples were obtained on the day that the study medication was dispensed and at 34 weeks’ gestation. Serum was stored at −80°C. 25(OH)D concentration was assessed by chemiluminescence immunoassay (Liaison automated platform, Diasorin, Minnesota, USA). All samples were analysed in a single batch ... | PMC10470377 | |
Delivery and infant details | blood loss, PPH | PRETERM BIRTH, BLOOD LOSS | Gestational age at birth and mode of delivery were collected by a research nurse/midwife from participants’ medical records. Preterm birth was defined as delivery before 37 weeks’ completed gestation. Mode of delivery was categorized as spontaneous vaginal delivery (SVD), instrumental vaginal delivery (i.e. forceps and... | PMC10470377 |
Statistical analysis | The analysis performed here was post hoc exploratory analysis that was not stated in the original trial protocol.Consort diagram. | PMC10470377 | ||
Ethics approval | The study was approved by the Southampton and South-West Hampshire Research Ethics Committee. MAVIDOS was registered prospectively (ISRCTN:82927713; EUDRACT:2007-001716-23); full approval from UK MHRA was granted, and written, informed consent was obtained from all participants. | PMC10470377 | ||
Results | A total of 1449 women consented to baseline 25(OH)D screening to determine the eligibility to participate in the full trial; 59 and 89 women were excluded due to 25(OH)D < 25 nmol/l and >100 nmol/l, respectively. A further 167 women withdrew prior to randomization. A total of 1134 women were initially randomized, and 9... | PMC10470377 | ||
Gestational age and birth weight at delivery | The proportion of male infants born in each group was similar (placebo 51.7%, cholecalciferol 53.9%, | PMC10470377 | ||
Mode of delivery | Mode of delivery differed between the two groups (Mode of delivery in women randomized to placebo or 1000 IU/day cholecalciferol during pregnancy ( | PMC10470377 | ||
Post-partum haemorrhage | PPH | POST-PARTUM HAEMORRHAGE | PPH occurred in 32.1% of women randomized to cholecalciferol and 38.1% of women randomized to placebo (RR 0.84, 95%CI 0.71,1.00). Findings were similar for major PPH, with wider confidence limits for this less frequent outcome (RR 0.77, 95%CI 0.52,1.15). Overall, PPH was more common in women requiring a Caesarean secti... | PMC10470377 |
Discussion | PMC10470377 | |||
Main findings of this study | PPH | PRETERM BIRTH, EARLY PREGNANCY | In this randomized, placebo-controlled trial, 1000 IU/day cholecalciferol during pregnancy in women with an early pregnancy 25(OH)D of 25–100 nmol/l did not alter the gestational age at delivery or the incidence of preterm birth. However, our findings suggest that antenatal vitamin D supplementation might be effective ... | PMC10470377 |
What is already known on this topic | PRETERM BIRTH | A systematic review of intervention studies of vitamin D supplementation has not shown that supplementation reduces the risk of preterm birth. | PMC10470377 | |
What this study adds | obesity, nerve injury, jaundice, psychological distress, PPH, bone mass, trauma | OBESITY, INTRACRANIAL HAEMORRHAGE, VITAMIN D DEFICIENCY, INFANT MORBIDITY | Supplementation with 1000 IU/day cholecalciferol did result in a difference in mode of delivery. The proportion of women having a SVD in those randomized to cholecalciferol was higher than the placebo group with fewer instrumental deliveries but no difference in Caesarean section. As instrumental delivery is associated... | PMC10470377 |
Limitations of this study | PREGNANCY COMPLICATIONS, VITAMIN D DEFICIENCY, RECRUITMENT, EARLY PREGNANCY | A key limitation was the exclusion of women with 25(OH)D < 25 nmol/l in early pregnancy due to ethical and governance issues. Further intervention studies are, therefore, required in women with vitamin D deficiency who might particularly benefit from supplementation. Over 95% of the MAVIDOS participants were of White e... | PMC10470377 | |
Conclusions | PRETERM BIRTH | In conclusion, in women with a baseline 25(OH)D 25-100 nmol/l, 1000 IU/day cholecalciferol during pregnancy did not reduce the incidence of preterm birth but was associated with a modest increase in the proportion who achieved a SVD and reduction in instrumental deliveries. Further trials are required to confirm this f... | PMC10470377 | |
Acknowledgements | C.C. and N.C.H. are joint senior authors. We are extremely grateful to Merck GmbH for the kind provision of the Vigantoletten supplement. Merck GmbH had no role in the trial execution, data collection, analysis or manuscript preparation. | PMC10470377 | ||
Data availability | Data is not publicly available. Requests for data access will be considered on application to Prof N Harvey. | PMC10470377 | ||
Funding | Arthritis | ARTHRITIS | This work was supported by grants from the Arthritis Research UK (17702), Medical Research Council (MC_PC_21003; MC_PC_21001), Bupa Foundation, National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust and NIH... | PMC10470377 |
Disclosure summary | Arthritis | ARTHRITIS | RJM, SK, IS, RF, SVG, SD, SC, AP, SMR, AJK and MF have nothing to disclose. CC reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. NCH reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bo... | PMC10470377 |
References | PMC10470377 | |||
Background | Chronic infectious wounds | Chronic infectious wounds seriously affect patients' quality of life. | PMC10782296 | |
Aim | chronic infectious wounds | To assess the effect of whole course seamless nursing mode on patients with chronic infectious wounds. | PMC10782296 | |
Methodology | pain | One hundred patients treated between January 2019 and December 2020 were randomly divided into control and observation groups (n=50) that were given routine nursing and whole course seamless nursing, respectively. Their pain score, comfort score, wound healing time, wound healing effect, psychological state scores, sle... | PMC10782296 | |
Results | grade-A, pain | Observation group had lower pain score and higher comfort score than those of control group after nursing (P<0.05). Compared with control group, observation group had shorter wound healing time and higher grade-A wound healing rate (P<0.05). The SDS and SAS scores of observation group were lower than those of control g... | PMC10782296 | |
Conclusion | chronic infectious wounds, pain | For patients with chronic infectious wounds, whole course seamless nursing effectively relieves wound pain, facilitates wound healing, improves comfort, psychological state and sleep status, and makes them more satisfied. | PMC10782296 | |
Introduction | Chronic infectious wounds | DELAYED WOUND HEALING, INFECTION INDUCED | Chronic infectious wounds refer to the wound infection induced by the invasion of pathogenic microorganisms after injury, leading to delayed wound healing or even unhealed wounds and seriously affecting patients' quality of life | PMC10782296 |
Materials and methods | PMC10782296 | |||
Subjects | chronic infectious wounds, chronic infectious wounds regarding the purpose | RECRUITMENT | Recruitment was carried out by educating patients with chronic infectious wounds regarding the purpose and significance of this study, and then they voluntarily participated in the study. We conducted a prospective case-control study and included 100 patients with chronic infectious wounds treated between January 2019 ... | PMC10782296 |
Interventions | hypertension, hypoglycemic, diabetes | HYPERTENSION, DISEASES, COMPLICATION, DIABETES | The control group was subjected to routine nursing. Specifically, the wound was cleaned and disinfected and the dressing was changed regularly according to the doctor's advice to ensure that the dressing was clean and dry until the wound healed.Patients in observation group were given whole course seamless nursing. A w... | PMC10782296 |
Statistical analysis | All data were statistically analysed by SPSS 22.0 software. The categorical variables were represented as percentage and analysed using the chi-square test. The continuous numerical variables were represented as mean ± standard deviation (-x ± s). The independent t test was used for comparison between groups at the sam... | PMC10782296 | ||
Results | PMC10782296 | |||
Socio-demographic characteristics of the study population | The control group included 27 males and 23 females aged 20-65 years old, (43.25±12.65) years on average. There were 22 cases of ASA grade II and 28 cases of grade III. The observation group consisted of 29 males and 21 females aged 20-64 years old, (42.91±12.73) years on average. There were 23 cases of ASA grade II and... | PMC10782296 | ||
Pain and comfort scores | Pain, pain | Compared with before nursing, pain score was significantly lower in the two groups after nursing, especially in observation group (P<0.05). After nursing, both groups, especially control group, had significantly increased comfort scores (P<0.05) (Pain and comfort scores (x̅ ± s, point)P<0.05 P<0.05 Paired t testindepen... | PMC10782296 | |
Wound healing results | grade-A | Compared with control group, observation group had shorter wound healing time, and higher grade-A wound healing rate (P<0.05) (Wound healing resultsP<0.05 Independent t testchi-square test | PMC10782296 | |
Psychological state scores | Compared with before nursing, SDS and SAS scores significantly decreased in the two groups after nursing, being more obvious in observation group (P<0.05) (Psychological state scores (χ̅ ± s, point)P<0.05 P<0.05 Paired t testindependent t test | PMC10782296 | ||
Sleep indices | After nursing, both groups, particularly observation group, had significantly improved actual sleep time, sleep latency and PSQI score compared with those before nursing (P<0.05) (Sleep indices (x̅ ± s)P<0.05 P<0.05 Paired t testindependent t test | PMC10782296 | ||
Quality-of-life scores | After nursing, the two groups had significantly higher quality-of-life scores than those before nursing, especially in observation group (P<0.05) (Quality-of-life scores (x̅ ± s, point)P<0.05 P<0.05 Paired t testindependent t test | PMC10782296 | ||
Nursing satisfaction rates | The overall nursing satisfaction rate of observation group exceeded that of control group (98.00% vs. 84.00%, P<0.05) (Nursing satisfaction rates (n (%))P<0.05 Chi-square test. | PMC10782296 | ||
Discussion | chronic infectious wounds, pain, Chronic infectious wounds | Chronic infectious wounds refer to wounds (due to various factors) infected with microorganisms during the healing stage, which are common in surgeryIt is clinically recommended to perform active therapies for chronic infectious wounds, such as dressing change treatment and vacuum sealing drainageIn conclusion, the app... | PMC10782296 | |
Acknowledgments | None. | PMC10782296 | ||
Conflict of interest | The authors have no conflicts of interest to report. | PMC10782296 | ||
ABSTRACT | PMC9970203 | |||
Background | RET, hypertrophy | HYPERTROPHY | Resistance exercise training (RET) is a common and well-established method to induce hypertrophy and improvement in strength. Interestingly, fish oil supplementation (FOS) may augment RET-induced adaptations. However, few studies have been conducted on young, healthy adults. | PMC9970203 |
Methods | RET | A randomized, placebo-controlled design was used to determine the effect of FOS, a concentrated source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to placebo (PL) on RET-induced adaptations following a 10-week RET program (3 days·week | PMC9970203 | |
Results | Twenty-one of 28 male and female participants (FOS, | PMC9970203 | ||
Conclusions | RET | When combined with RET, FOS improves absolute and relative 1RM upper-body and relative 1RM lower-body strength to a greater extent than that observed in the PL group of young, recreationally trained adults. | PMC9970203 | |
KEYWORDS | PMC9970203 | |||
Background | RET, hypertrophy, FM | HYPERTROPHY | The preservation and promotion of skeletal muscle mass and strength is critical for physical performance and healthy physiology throughout the lifespan [The incorporation of EPA and DHA into skeletal muscle phospholipid has been shown to enhance both nutrient and mechanically sensitive anabolic signaling proteins known... | PMC9970203 |
Methods | PMC9970203 | |||
Study design | RET | A randomized, single-blind, parallel-group design was used to examine the effects of FOS compared to placebo (PL) on body composition and strength during a 10-week RET program in young adults. Regarding blinding, one of the outcome assessors was aware of the allocations; however, all outcomes were conducted with other ... | PMC9970203 | |
Subjects | RET, chronic diseases, type-2 diabetes mellitus | HEART DISEASE, CHRONIC DISEASES, DISORDERS | Twenty-eight young male (n = 12) and female (n = 16) adults were recruited from the local central Texas area and university population for this study. All participants met the following criteria: 1) between 18 and 40 years, 2) free from neuromuscular/musculoskeletal disorders and known chronic diseases (heart disease, ... | PMC9970203 |
Supplementation protocol | Groups were supplemented with FO (4.5 g∙d | PMC9970203 | ||
Resistance training procedures | As illustrated in Initial training loads were selected based on 70% of the subject’s baseline 1RMs. The load was adjusted for all exercises based on the subject’s ability to reach momentary concentric failure between 8-12 repetitions. The load was decreased at the next training session if the subject completed less tha... | PMC9970203 | ||
Dietary records | RET | Subjects were required to submit three-day food logs (two weekdays, one weekend day) before and after the RET intervention using the MyFitnessPal mobile or desktop application (MyFitnessPal; San Francisco, CA, USA). Additionally, LC n-3 PUFA intake was assessed using a food frequency questionnaire (FFQ) that has been v... | PMC9970203 | |
Fatty acid dried blood spot | FAPS | REGRESSION | Fatty acid dried blood spot (DBS) was obtained to track supplementation compliance and ensure adequate LC n-3 PUFA membrane incorporation. A drop of blood was collected from each participant via finger stick on filter paper pre-treated with a preservation solution (Fatty Acid Preservative Solution, FAPS™) and allowed t... | PMC9970203 |
Statistical analyses | All statistical analyses were performed using IBM SPSS version 28 (Armonk, NY, USA). Data were tested for normality and homogeneity using the Shapiro-Wilks and Levene’s tests, respectively. Baseline characteristics were analyzed using an independent samples | PMC9970203 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.